GeoVax Strengthens Intellectual Property Portfolio with Allowance of Multi-Antigen COVID-19 Vaccine Patent
TL;DR
GeoVax's new patent strengthens its multi-antigen COVID-19 vaccine portfolio, offering a competitive edge with broader and more durable protection against variants than single-antigen vaccines.
The patent covers MVA viral vectors encoding Spike, Membrane, and Envelope proteins that form virus-like particles to induce both antibody and T-cell immune responses.
This innovation aims to provide better protection for immunocompromised populations and help combat evolving variants, improving global health outcomes against COVID-19.
GeoVax's vaccine mimics the natural virus structure with multiple antigens, creating virus-like particles for enhanced immune recognition and broader variant coverage.
Found this article helpful?
Share it with your network and spread the knowledge!
The U.S. Patent and Trademark Office has issued a Notice of Allowance for GeoVax Labs' patent application covering recombinant Modified Vaccinia Ankara viral vectors that encode multiple SARS-CoV-2 proteins. These constructs are designed to generate virus-like particles that induce both antibody and T-cell responses, providing durable and broad immune protection against current and emerging variants of the virus.
The allowed claims broadly cover multi-antigen designs including Spike, Membrane, and Envelope proteins to mimic the natural virus structure and induce robust immune responses. This technology enables VLP formation within host cells, allowing presentation of antigens in their natural conformation for optimal immune recognition. The patent also covers both ancestral strain sequences and variant-associated mutations such as K417N/T, E484K, and N501Y to address potential immune escape by new variants.
David Dodd, GeoVax President and CEO, stated that this Notice of Allowance represents an important strengthening of the company's intellectual property estate protecting next-generation, multi-antigen COVID-19 vaccines. Unlike single-antigen vaccines, the MVA-based multi-antigen constructs are designed to elicit durable, broad-spectrum protection even as the virus continues to evolve. The newly allowed patent covers constructs central to the company's CM01 and CM02 candidates, which express multiple SARS-CoV-2 proteins to generate virus-like particles in vaccinated individuals.
Together with GEO-CM04S1, which is advancing through Phase 2 clinical trials in immunocompromised and healthy populations, CM01 and CM02 position GeoVax as a leader in next-generation COVID-19 vaccine innovation. This portfolio is uniquely differentiated from single-antigen approaches such as mRNA vaccines. The company's technology is designed to provide broad and durable protection by engaging both arms of the immune system and countering immune escape by new viral variants. For more information about the company's clinical trials and updates, visit https://www.geovax.com.
The allowance of this patent could have significant implications for the future of COVID-19 vaccination strategies, particularly as the virus continues to mutate and evolve. Multi-antigen approaches may offer more comprehensive protection against emerging variants, potentially reducing the need for frequent booster shots and providing longer-lasting immunity. This development strengthens GeoVax's position in the competitive vaccine market and may influence how other companies approach vaccine design for rapidly mutating viruses.
Curated from NewMediaWire
